Income Assistance Plays Role In Addressing Social Determinants Of Health – 2018 Update On SSI & TANF Trends Released By OPEN MINDS
June 01, 2018 14:01 ET
|
Open Minds
Gettysburg, PA, June 01, 2018 (GLOBE NEWSWIRE) -- A new report from OPEN MINDS highlights the connection between poverty and poor health outcomes, and explores how an income assistance program could...
Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress
December 19, 2017 12:45 ET
|
Qu Biologics
VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer
November 28, 2017 12:43 ET
|
Qu Biologics
VANCOUVER, British Columbia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers
October 03, 2017 12:16 ET
|
Qu Biologics
VANCOUVER, British Columbia , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Positive feedback from FDA reviewers in response to Pre-IND meeting package
August 14, 2017 13:56 ET
|
Qu Biologics
VANCOUVER, British Columbia, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement
August 02, 2017 12:29 ET
|
Qu Biologics
VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Qu Biologics invited to present at US National Cancer Institute (NCI) Conference
July 12, 2017 17:06 ET
|
Qu Biologics
VANCOUVER, British Columbia, July 12, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Qu Biologics invited to present Research Data at International Scientific Meetings
May 03, 2017 12:47 ET
|
Qu Biologics
VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease
April 19, 2017 15:26 ET
|
Qu Biologics
VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Innovation Grant Awarded for Qu Biologics Project with University of Ottawa Scientist
April 04, 2017 15:15 ET
|
Qu Biologics
VANCOUVER, British Columbia, April 04, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...